Media coverage about CareDx (NASDAQ:CDNA) has been trending somewhat positive this week, Accern reports. The research group identifies negative and positive news coverage by analyzing more than twenty million news and blog sources in real-time. Accern ranks coverage of companies on a scale of negative one to one, with scores closest to one being the most favorable. CareDx earned a media sentiment score of 0.17 on Accern’s scale. Accern also gave headlines about the company an impact score of 45.6152373597986 out of 100, indicating that recent news coverage is somewhat unlikely to have an impact on the stock’s share price in the next several days.
Here are some of the headlines that may have impacted Accern’s rankings:
Several analysts have issued reports on CDNA shares. HC Wainwright reaffirmed a “buy” rating and issued a $12.00 target price on shares of CareDx in a research note on Wednesday, January 31st. ValuEngine raised CareDx from a “sell” rating to a “hold” rating in a research note on Friday, February 2nd. TheStreet raised CareDx from a “d-” rating to a “c-” rating in a research note on Tuesday, April 10th. Finally, BidaskClub raised CareDx from a “hold” rating to a “buy” rating in a research note on Friday, April 20th. One equities research analyst has rated the stock with a hold rating, five have issued a buy rating and one has issued a strong buy rating to the stock. The stock currently has an average rating of “Buy” and an average target price of $9.05.
Shares of CDNA opened at $11.00 on Friday. The company has a market capitalization of $398.70 million, a price-to-earnings ratio of -14.29 and a beta of 0.34. The company has a quick ratio of 0.50, a current ratio of 2.43 and a debt-to-equity ratio of 0.29. CareDx has a 1 year low of $10.97 and a 1 year high of $11.36.
CareDx (NASDAQ:CDNA) last issued its earnings results on Thursday, May 10th. The company reported ($0.14) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.13) by ($0.01). CareDx had a negative return on equity of 158.93% and a negative net margin of 115.91%. The firm had revenue of $14.05 million during the quarter, compared to analysts’ expectations of $13.91 million. sell-side analysts anticipate that CareDx will post -0.49 earnings per share for the current fiscal year.
In other CareDx news, insider Peter Maag sold 15,000 shares of the business’s stock in a transaction that occurred on Tuesday, March 27th. The stock was sold at an average price of $7.87, for a total value of $118,050.00. Following the completion of the sale, the insider now owns 272,037 shares in the company, valued at $2,140,931.19. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, major shareholder Neil Gagnon acquired 10,136 shares of the stock in a transaction on Thursday, April 26th. The stock was bought at an average price of $9.42 per share, with a total value of $95,481.12. Following the transaction, the insider now directly owns 928,768 shares of the company’s stock, valued at approximately $8,748,994.56. The disclosure for this purchase can be found here. Insiders own 5.40% of the company’s stock.
CareDx Company Profile
CareDx, Inc is a molecular diagnostics company. The Company is focused on the discovery, development and commercialization of clinically differentiated diagnostic surveillance solutions for transplant patients. The Company’s commercialized testing solution, the AlloMap heart transplant molecular test (AlloMap), is a gene expression test that helps clinicians monitor and identify heart transplant recipients with stable graft function having a low probability of moderate/severe acute cellular rejection.
Receive News & Ratings for CareDx Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CareDx and related companies with MarketBeat.com's FREE daily email newsletter.